A recent association between Harvard Medical School, Bucknell University, and University of Cyprus has established guidelines for the design of nanomedicines with optimal therapeutic effects in cancer cells.
The guidlines were published in the September issue of Annals of Biomedical Engineering.
Researchers introduced a multi-stage delivery system comprising a 20-nm primary nano-carrier, which releases 5-nm secondary nanoparticles containing drugs, through mathematical modelling.
The researchers also found that multi-stage nanoparticles have better therapeutic outcomes than conventional two-stage nano-carriers.
The smaller size of the primary particles of 20 nm also displayed better penetration into tumor tissues, compared with 100-nm particles used in previous researches.